Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients.

BACKGROUND Estrogen receptor beta (ERβ) belongs to a large family of nuclear receptors. Recent studies have suggested that ERβ in contrast to ERα might act as a tumour suppressor in ovarian cancer (OVCA). MATERIALS AND METHODS Expression of ERβ was detected by immunocytochemistry in 11 OVCA cell lines and by immunohistochemistry in 43 (41 FIGO stage III) OVCA specimens prepared before chemotherapy and 30 specimens from the same group after chemotherapy. Cisplatin sensitivity in the 11 cell lines was also analysed. RESULTS No significant correlations between cisplatin-sensitivity and expression of ERβ was found in the cell lines. In the cases which responded well to chemotherapy (complete response) ERβ expression at preliminary laparotomy (PL) was significantly higher (p = 0.0004) than in those with progressive disease. Kaplan-Meier analysis revealed that the patients with higher ERβ expression (>30% of cells) at PL had an increased overall survival time and progression-free time (p = 0.00161 and p = 0.03255, respectively) than the patients with lower ERβ expression. Significantly shorter overall survival time characterized the cases with lower immunoreactivity score of ERβ expression at secondary cytoreduction (SCR) (p = 0.00346). CONCLUSION The loss of ERβ expression in ovarian tumours may be a feature of malignant transformation.

[1]  P. Leung,et al.  Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. , 2008, Molecular endocrinology.

[2]  H. Ngan,et al.  Estrogen Receptor Subtypes in Ovarian Cancer: A Clinical Correlation , 2008, Obstetrics and gynecology.

[3]  D. Mitter,et al.  Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells , 2007 .

[4]  M. Zabel,et al.  Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. , 2007, Oncology reports.

[5]  Manfred Dietel,et al.  ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome , 2006, Clinical Cancer Research.

[6]  M. Dietel,et al.  CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients. , 2006, Anticancer research.

[7]  H. Lage,et al.  RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. , 2006, Biochemical and biophysical research communications.

[8]  M. Dietel,et al.  Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. , 2006, Histology and histopathology.

[9]  G. Lazennec.  Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. , 2006, Cancer letters.

[10]  H. Lage,et al.  Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cells , 2005, International journal of cancer.

[11]  H. Lage,et al.  Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  D. Katsaros,et al.  Involvement of Estrogen Receptor β in Ovarian Carcinogenesis , 2004, Cancer Research.

[13]  P. Pujol,et al.  Estrogens and epithelial ovarian cancer. , 2004, Gynecologic oncology.

[14]  J. Gustafsson,et al.  Estrogen and progesterone receptors in ovarian epithelial tumors , 2004, Molecular and Cellular Endocrinology.

[15]  V. Jordan,et al.  The biological role of estrogen receptors α and β in cancer , 2004 .

[16]  G. Gatta,et al.  Cancer survival in European adolescents and young adults. , 2003, European journal of cancer.

[17]  R. L. Baldwin,et al.  Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. , 2003, American journal of obstetrics and gynecology.

[18]  J. Kurebayashi,et al.  Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance , 2003, Breast cancer.

[19]  S. Gapstur,et al.  Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. , 2001, Journal of the National Cancer Institute.

[20]  S. Kaye,et al.  Recent advances in the treatment of epithelial ovarian cancer , 2001, Expert opinion on investigational drugs.

[21]  K. Münstedt,et al.  Steroid hormone receptors and long term survival in invasive ovarian cancer , 2000, Cancer.

[22]  G. Mor,et al.  Absence of Estrogen Receptor‐β Expression in Metastatic Ovarian Cancer , 2000 .

[23]  T. Tamaya,et al.  Clinical Significance of Expression of Estrogen Receptor α and β mRNAs in Ovarian Cancers , 2000, Oncology.

[24]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma , 1998, Cancer.

[25]  S. Howell,et al.  Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. , 1994, British Journal of Cancer.

[26]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.